Aztreonam + Gentamicin

The aztreonam + gentamicin combination is an antibiotic regimen that combines two distinct antimicrobial agents with complementary mechanisms of action. This combination has been studied for its synergistic effects against various gram-negative bacterial infections, particularly those caused by Pseudomonas aeruginosa.

Pharmacology and Mechanism of Action

Aztreonam is a monobactam antibiotic that works by inhibiting bacterial cell wall synthesis. It selectively targets gram-negative aerobic bacteria while having minimal activity against gram-positive bacteria. Aztreonam binds to penicillin-binding proteins (PBPs) in susceptible bacteria, disrupting cell wall formation and leading to bacterial cell death.

Gentamicin is an aminoglycoside antibiotic that functions by binding to the 30S subunit of the bacterial ribosome, which interferes with protein synthesis. This binding forces adenosines to maintain positions that lead to the acceptance of incorrect amino acid-tRNAs, resulting in the production of non-functional, mistranslated proteins that misfold and aggregate, eventually killing the bacterium.

When combined, aztreonam and gentamicin have demonstrated synergistic activity against many gram-negative bacteria, including:

• Most strains of Pseudomonas aeruginosa
• Many strains of Enterobacteriaceae
• Other gram-negative aerobic bacilli

Clinical Applications

The aztreonam + gentamicin combination has been studied for treating:

1. Lower respiratory tract infections due to Pseudomonas aeruginosa 2. Enterobacter aerogenes endocarditis 3. Infections in patients with cystic fibrosis 4. Pseudomonas cepacia infections

In clinical studies, the combination has shown impressive efficacy:

• In one multicenter study of lower respiratory tract infections due to P. aeruginosa, the clinical response rate was 84% (48/57 patients), including 47% complete cures and 37% partial responses
• The microbiological response rate in the same study was 69% (35/51 patients)
• The combination was synergistic in 72% of initial isolates from patients

Dosing

Typical dosing regimens used in studies include:

• Aztreonam: 2 g every 8 hours
• Gentamicin: 3 to 5 mg/kg per day in three equal doses

Alternative dosing used in animal studies:

• Aztreonam: 60 mg/kg every 6 hours
• Gentamicin: 1.7 mg/kg every 8 hours

Pharmacokinetics

When administered separately:

• Aztreonam:

  • Peak serum level: approximately 135 μg/ml
  • Half-life: 0.7 hours (in animal studies)
  • In humans with normal renal function, the serum half-life averages 1.7 hours (1.5 to 2)
  • Serum protein binding: approximately 56%

• Gentamicin:

  • Peak serum level: approximately 7.4 μg/ml
  • Half-life: 1.3 hours (in animal studies)

Single-dose intravenous pharmacokinetic studies have not shown any significant interaction between aztreonam and concomitantly administered gentamicin.

Safety and Tolerability

The aztreonam + gentamicin combination was generally well tolerated in clinical studies. In one study, two patients were withdrawn due to rashes that emerged during treatment. The combination may offer advantages over other antibiotic combinations with regard to toxicity.

This combination represents an important therapeutic option for serious gram-negative infections, particularly in cases where synergistic activity is desired to enhance efficacy or prevent the emergence of resistance.